Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Ungünstige Tumorbiologie - Kinderwunsch - jahrelange Nachsorge

Mammakarzinom bei jungen Frauen: Was Sie wissen sollten

  • 7 Accesses

This is a preview of subscription content, log in to check access.


  1. 1.

    Paluch-Shimon S et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast. 2017;35:203-17

  2. 2.

    DeSantis C et al. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52-62

  3. 3.

    Leclere B et al. Trends in incidence of breast cancer among women under 40 in seven European countries: a GRELL cooperative study. Cancer Epidemiol. 2013;37(5):544-9

  4. 4.

    Pronzato P et al. Biological characteristics and medical treatment of breast cancer in young women-a featured population: results from the NORA study. Int J Breast Cancer. 2011;

  5. 5.

    Banz-Jansen C et al. Characteristics and therapy of premenopausal patients with early-onset breast cancer in Germany. Arch Gynecol Obstet. 2012;286(2):489-93

  6. 6.

    American Cancer Society. Breast Cancer Facts & Figures 2013-2014. Atlanta: American Cancer Society, Inc. 2013.

  7. 7.

    Couch FJ et al. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol. 2017;3(9):1190-6

  8. 8.

    Kwon JS et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010;28(27):4214-20

  9. 9.

    Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms. AWMF-Registernummer: 032-045OL 2018; Langversion 4.1

  10. 10.

    Saha P et al. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol. 2017;35(27):3113-22

  11. 11.

    Vila J et al. Overall survival according to type of surgery in young (</=40 years) early breast cancer patients: A systematic meta-analysis comparing breast-conserving surgery versus mastectomy. Breast. 2015;24(3):175-81

  12. 12.

    Robson ME et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558-66

  13. 13.

    Schmid et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):2108-21

  14. 14.

    Qi WX et al. Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials. Breast. 2013;22:314-9

  15. 15.

    Cardoso F et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol. 2018;29(8):1634-57

Download references

Author information

Correspondence to Dr. med. Maximiliane Burgmann.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Burgmann, M. Mammakarzinom bei jungen Frauen: Was Sie wissen sollten. Im Fokus Onkologie 23, 25–28 (2020).

Download citation